Drug Profile
EC 5026
Alternative Names: BPN-19186; EC-5026Latest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator EicOsis
- Class Analgesics; Fluorobenzenes; Non-opioid analgesics; Piperidines; Small molecules; Urea compounds
- Mechanism of Action Epoxide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neuropathic pain; Pain
Most Recent Events
- 30 Jan 2024 EicOsis plans to initiate its first pain patient study in April 2024
- 17 Jan 2024 Phase-I development is in Pain ongoing in USA (EicOsis pipeline, January 2024)
- 17 Jan 2024 Early research in Pain (Combination therapy) and Gastrointestinal disorders (Prevention) is underway in USA, prior to January 2024 (EicOsis pipeline January 2024)